APELOA(SZ:000739) KAIYUAN SECURITIES·2025-10-23 04:13Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's CDMO (Contract Development and Manufacturing Organization) business continues to grow rapidly, with a significant order backlog. Despite a decline in overall revenue and net profit for the first three quarters of 2025, the CDMO segment showed strong performance with a revenue increase of 20% [4][5]. - The projected net profit for 2025-2027 has been adjusted downwards due to pressure on the raw material intermediate business, with expected net profits of 9 billion, 11.89 billion, and 14.95 billion respectively [4][5]. Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 77.64 billion (down 16.43% year-on-year) and a net profit of 7.00 billion (down 19.48% year-on-year) [4]. - The gross margin for the same period was 25.02% (up 0.79 percentage points), while the net margin was 9.02% (down 0.34 percentage points) [4]. - In Q3 2025, revenue was 23.19 billion (down 18.94% year-on-year) with a net profit of 1.37 billion (down 43.95% year-on-year) [4]. CDMO Business Insights - The CDMO business generated revenue of 16.9 billion in the first three quarters of 2025, reflecting a 20% increase, with a gross margin of 44.5% (up 3.7 percentage points) [5]. - The company has 1,343 quoted projects (up 68%) and approximately 670 clients, with 391 commercial projects (up 15%) and 853 clinical projects (up 41%) [5]. - The total order amount for the CDMO business to be delivered in the next 2-3 years is 5.2 billion, excluding the upcoming deliveries in Q4 2025 [5]. Research and Development - As of Q3 2025, the company has a research and development team of 1,300 people, with approximately 900 dedicated to CDMO [6]. - The sales expense ratio, management expense ratio, R&D expense ratio, and financial expense ratio for the first three quarters of 2025 were 4.93%, 4.03%, 5.99%, and -0.37% respectively, showing slight increases year-on-year [6]. Financial Projections - The company's projected revenue for 2025 is 107.54 billion, with a year-on-year decline of 10.5% [7]. - The projected net profit for 2025 is 900 million, reflecting a year-on-year decrease of 12.7% [7]. - The expected P/E ratios for 2025, 2026, and 2027 are 19.6, 14.8, and 11.8 respectively, indicating a high valuation attractiveness [4][7].